Anticoagulant and Antiplatelet Agents in Patients Undergoing Vitreoretinal Surgery

This study has been completed.
Sponsor:
Information provided by:
Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier:
NCT01020656
First received: November 24, 2009
Last updated: NA
Last verified: November 2009
History: No changes posted
  Purpose

Purpose: To establish the prevalence of anticoagulant, aspirin, and clopidogrel use in patients undergoing vitreoretinal surgery, and to compare the outcome of peribulbar anesthesia between users and non-users.


Condition
Retinal Detachment

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Maintenance of Anticoagulant and Antiplatelet Agents for Patients Undergoing Vitreoretinal Surgery

Resource links provided by NLM:


Further study details as provided by Centre Hospitalier Universitaire Dijon:

Enrollment: 206
Study Start Date: January 2009
Study Completion Date: June 2009
Primary Completion Date: June 2009 (Final data collection date for primary outcome measure)
Groups/Cohorts
group 1
patients with no anticoagulants used as the control group
group 2
patients treated with anticoagulant therapy (warfarin, fluindone, acenocoumarol)
group 3
patients treated with aspirin
group 4
patients treated with clopidogrel therapy
group 5
patients treated with both anticoagulant and aspirin medications
group 6
patients treated with both anticoagulant and clopidogrel medications
group 7
patients treated with both aspirin and clopidogrel medications

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

We analyzed the chart of 239 eyes (206 patients) which underwent posterior segment surgery with peribulbar anesthesia.

Criteria

Inclusion Criteria:

  • Take or no anticoagulant treatment before surgery,
  • Vitreoretinal surgery

Exclusion Criteria:none

  • No surgery
  • Anesthetic complication
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01020656

Locations
France
Ophthalmology Unit CHU Dijon
Dijon, Burgundy, France, 21000
Sponsors and Collaborators
Centre Hospitalier Universitaire Dijon
  More Information

No publications provided

Responsible Party: Professor Catherine Creuzot-Garcher, Centre Hospitalier Universitaire Dijon
ClinicalTrials.gov Identifier: NCT01020656     History of Changes
Other Study ID Numbers: MARIE02
Study First Received: November 24, 2009
Last Updated: November 24, 2009
Health Authority: France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Keywords provided by Centre Hospitalier Universitaire Dijon:
anticoagulant agents
antiplatelet agents
vitreoretinal surgery
Patients suffered from retinal detachment

Additional relevant MeSH terms:
Retinal Detachment
Retinal Diseases
Eye Diseases
Anticoagulants
Platelet Aggregation Inhibitors
Hematologic Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on August 21, 2014